Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
18.16
+0.12 (0.67%)
At close: Apr 28, 2026, 4:00 PM EDT
18.16
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Dyne Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Dyne Therapeutics stock have an average target of 37, with a low estimate of 16 and a high estimate of 50. The average target predicts an increase of 103.74% from the current stock price of 18.16.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 9, 2026.
Analyst Ratings
The average analyst rating for Dyne Therapeutics stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 6 | 9 | 9 | 9 | 7 | 6 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 17 | 17 | 17 | 15 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $38 | Strong Buy | Maintains | $38 | +109.25% | Mar 9, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $50 → $47 | Buy | Maintains | $50 → $47 | +158.81% | Mar 3, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $38 | Strong Buy | Maintains | $38 | +109.25% | Mar 3, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $50 | Strong Buy | Maintains | $60 → $50 | +175.33% | Mar 3, 2026 |
| JP Morgan | JP Morgan | Hold Maintains $17 → $16 | Hold | Maintains | $17 → $16 | -11.89% | Jan 20, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
97.25M
EPS This Year
-2.99
from -3.47
EPS Next Year
-2.95
from -2.99
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 247.5M | ||||||
| Avg | n/a | 97.3M | ||||||
| Low | n/a | 19.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.80 | -1.76 | ||||||
| Avg | -2.99 | -2.95 | ||||||
| Low | -4.13 | -4.58 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.